Phase 2 N=106 Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas
Solid Tumors · Lymphomas
Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAE) — 3; 3; 3; 3 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=8 A Study in Subjects With Retinitis Pigmentosa
Retinitis Pigmentosa
Primary: Number of Subjects With Serious Adverse Events — 0; 0 Participants
Phase 2 N=123 A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma
Multiple Myeloma
Primary: Percentage of Participants Who Achieved a Complete Response (CR) by International Myeloma Working Group (IMWG) Criteria — 4.9; 12.2; 0 percentage of participants
Phase 2 N=60 Caplyta in Borderline Personality Disorder
Borderline Personality Disorder
Primary: Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) — 8.74; 5.80 Score on a scale
Phase 2 N=32 COVID Protection After Transplant-Immunosuppression Reduction
Kidney Transplant Recipients · Liver Transplant Recipients
Primary: The -Fold Change in Antibody Titer (Using the Roche Elecsys® Anti-SARS-CoV-2 S Assay) From Before Receiving the Study Dose of Vaccine to 30 Days After the Study Dose of…
Phase 2 N=42 Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma
Pancreatic Ductal Adenocarcinoma
Primary: 12- Month Overall Survival (OS) — 16 Participants
Phase 2 N=32 Pre-operative Treatment for Patients With Untreated Pancreatic Cancer
Resectable Pancreatic Cancer · Unresectable Pancreatic Cancer · Pancreatic Adenocarcinoma
Primary: CA 19-9 Normalization — 40; 13.6; 30; 50 Percentage of participants — p=0.235
Phase 2 N=35 A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer
Colorectal Cancer
Primary: Durable Clinical Benefit — 3; 32 Participants
Phase 2 N=50 Patient-Reported Outcomes Following Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Primary: Number of Patients With PRO-CTCAE Adverse Events With Score ≥ 3 — 8; 5; 5; 1 participants
Phase 2 N=104 A Study of Psilocybin for Major Depressive Disorder (MDD)
Depressive Disorder, Major
Primary: Change in Central Rater Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to Post-dose Day 43 — -19.1; -6.8 units on a scale — p=<0.001
Phase 2 N=27 Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)
Marginal Zone B-cell Lymphoma
Primary: Overall Response Rate — 81.8 Percentage
Phase 2 N=98 Efficacy of LAMA Added to ICS in Treatment of Asthma (ELITRA)
Asthma
Primary: FEV1 AUC0-12h Normalized by Time on Day 42 (ITT Population) — 2.470; 2.373 liters — p=<0.001
Phase 2 N=35 Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients
Hypertension Pulmonary Secondary Heart Failure · Right Sided Heart Failure With Normal Ejection Fraction · Heart Failure With Normal Ejection Fraction
Primary: Clinical Safety — 33 Participants
Phase 2 N=8 Gene Transfer for Severe Combined Immunodeficiency, X-linked (SCID-X1) Using a Self-inactivating (SIN) Gammaretroviral Vector
Severe Combined Immunodeficiency
Primary: CD3 Cell Count Post Infusion — 5; 3 Participants
Phase 2 N=76 Abbreviated Protocol for Two-Stage Exchange
Prosthetic Joint Infection
Primary: Composite Endpoint of Overall Success at 90 Days — 33; 11 Participants — p=<0.0001